MaaT Pharma Completes a Capital Increase of €13 Million

• Positive results from Phase 3 trial for MaaT013 in acute Graft-versus-Host disease (aGvHD); topline results (January 2025) showed a 62% gastrointestinal overall response rate at Day 28 and 1-year expected Overall Survival of 54%, demonstrating high efficacy and significant improvement over currently available therapies; Positive final DSMB review confirming remarkable efficacy results and a positive benefit/risk profile.
• Marketing Authorization Application (MAA) in Europe for MaaT013 on track for EMA submission in June 2025.
  Initiation of Expanded Access for MaaT013 in aGvHD in the U.S.
• EAP Revenues of €3.2 million in 2024, a 44% increase over 2023, and the highest revenues generated from the EAP to date.
• As of December 31, 2024, cash and cash equivalents were €20.2 million.
• Capital Increase of €13 million supported by historical shareholders to advance towards its next significant operational and financing milestones, extending its cash runway into October 2025.

Read the press release